Introduction {#sec1-1}
============

Hand-foot syndrome (HFS) is a relatively frequent adverse reaction to certain anticancer chemotherapies. The syndrome can present initially as erythema, dysesthesias, and swelling of palms and soles, and can further progress to the stage of blisters formation and rarely ulceration.\[[@ref1]\] This sequence of events can limit daily functions and may affect the quality of life. The most commonly implicated drug is 5-fluorouracil or its prodrug or oral capecitabine. Treatment of this syndrome is generally supportive. Paclitaxel-induced HFS is rare, with few case reports in the literature.

Case Report {#sec1-2}
===========

A 52-year-old gentleman, known case of carcinoma buccal mucosa on palliative chemotherapy, presented to us with complaints of pain, erythema, and desquamation over dorsal aspect of the hand and soles 7 days before presentation (Grade 3). On further enquiry, the patient had taken the first cycle of injectable chemotherapy, i.e., injection paclitaxel (260 mg) in combination with carboplatin (500 mg) 20 days prior. On examination, the dorsal aspect of the bilateral hands and feet showed the presence of erythema and desquamation \[Figures [1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}\]. On taking the drug history, as per the literature review, injection paclitaxel is known to cause hand-foot-mouth syndrome albeit rarely with only few case reports addressing the same. As per the Naranjo Scale, the causality score was 7, and as per the scale, the causality is "probable." The other drug, i.e., carboplatin which formed the chemotherapy doublet in our case, has never been mentioned in the literature to cause to cause HFS. Hence, as per the literature review and causality score on Naranjo Scale, paclitaxel-induced hand-foot-mouth syndrome was kept as the tentative diagnosis. The patient was given supportive care, topical emollients, tablet pyridoxine (Vitamin B6). After 10 days, there was gradual resolution of the signs and symptoms. From the subsequent cycles, chemotherapy regimen was changed to methotrexate + 5-fluorouracil weekly as patient treatment intent was palliative and we did not re-challenge the patient with the paclitaxel.
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Discussion {#sec1-3}
==========

HFS, also known as palmar-plantar erythrodysesthesia, acral erythema, or Burgdorf reaction, was described in 1974 in a patient receiving mitotane (Lysodren).\[[@ref2]\] Since then, various drugs causing HFS has been described, for example, infusional 5-fluorouracil, capecitabine,\[[@ref3]\] vinorelbine, liposomal doxorubicin, hydroxyurea, mercaptopurine, intravenous cyclosporine, methotrexate, cyclophosphamide, cytosine arabinoside, sunitinib, and sorafenib.

Symptoms of HFS can occur as early as 24 h after treatment initiation or as late as 10 months after treatment continuation.\[[@ref2][@ref4]\]

Various mechanisms explaining the occurrence of HFS are as follows:

Chemotherapy drug leak out of the capillaries into the hands and feet damaging the surrounding tissues\[[@ref5]\]High proliferation rate of epidermal basal cells in the palms making them more sensitive to the local action of cytotoxic drugs\[[@ref6]\]Concentration of drugs within eccrine sweat glands of palms and soles\[[@ref7]\]Repeated friction and pressure over palms, soles, and fingertips increases the predisposition to this syndrome.\[[@ref6]\]

The symptoms usually start as a localized numbness, tingling, dysesthesia or paresthesia, and erythema over the palms and soles. They can be accompanied by swelling and discomfort. In severe cases, blistering, ulceration, desquamation, and incapacitating pain occur.

Grading of HFS is done according to the National Cancer Institute and the World Health Organization scale.\[[@ref8]\]

Three major histologic features central to the HFS are dyskeratotic keratinocytes at various stages of necrosis, basal layer vacuolar degeneration, and mild perivascular or lichenoid lymphocyte-predominant infiltrate.\[[@ref4][@ref9]\]

Only recommendation available with respect to the management of HFS includes drug discontinuation or modification. Some measures that have been suggested for the alleviation of symptoms include cold compresses, application of emollients, and avoidance of mechanical stress on the affected areas. Other supportive measures include tablet pyridoxine\[[@ref10]\] and analgesics if pain is present. Paclitaxel-induced HFS is rare and is being reported sparingly in the literature.\[[@ref10][@ref11][@ref12][@ref13]\] Hence, in this case, paclitaxel-induced HFS was a tentative diagnosis based on the literature review, Naranjo scale causality score. In our case, paclitaxel was discontinued as the intent of the treatment was palliative; however, in other case report by Assi *et al*.,\[[@ref13]\] paclitaxel was continued safely without any further resurgence of the HFS manifestation. This case has been presented to earmark rarer side effect of paclitaxel so that one must be aware of it because they can be easily confused with bacterial or fungal infections, leading to florid presentation if dose modification or change of therapy is not done and supportive therapy is not given.

Learning points {#sec2-1}
---------------

HFS though rare with paclitaxel, this rare side effect must be borne in mindIn case of paclitaxel, careful adjustment of dose may be required.
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